RU2011149334A - Анти-il-17f антитела и способы их применения - Google Patents
Анти-il-17f антитела и способы их применения Download PDFInfo
- Publication number
- RU2011149334A RU2011149334A RU2011149334/10A RU2011149334A RU2011149334A RU 2011149334 A RU2011149334 A RU 2011149334A RU 2011149334/10 A RU2011149334/10 A RU 2011149334/10A RU 2011149334 A RU2011149334 A RU 2011149334A RU 2011149334 A RU2011149334 A RU 2011149334A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- subject
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 20
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract 9
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 4
- 239000000710 homodimer Substances 0.000 claims abstract 4
- 208000024891 symptom Diseases 0.000 claims 6
- 230000002917 arthritic effect Effects 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Выделенное полностью человеческое моноклональное анти-IL-17F антитело, или его фрагмент, где указанное антитело включает:(a) область VCDR1, содержащую аминокислотную последовательность по SEQ ID NO: 45, 48, 51, 64, 67 или 70;(b) область VCDR2, содержащую аминокислотную последовательность по SEQ ID NO: 46, 49, 52, 54, 62, 65, 68, 71 или 73;(c) область VCDR3, содержащую аминокислотную последовательность по SEQ ID NO: 47, 50, 53, 55, 63, 66, 69 или 72;(d) область VCDR1, содержащую аминокислотную последовательность по SEQ ID NO: 74, 77, 80, 85, 91 или 94;(e) область VCDR2, содержащую аминокислотную последовательность по SEQ ID NO: 75, 78, 81, 83, 86, 92 или 96; и(f) область VCDR3, содержащую аминокислотную последовательность по SEQ ID NO: 76, 79, 82, 84, 93, 95, 97, 98 и 99, причем указанное антитело связывает IL-17F.2. Антитело по п.1, отличающееся тем, что не связывает гомодимер IL-17A.3. Антитело по п.1, отличающееся тем, что представляет изотип IgG.4. Антитело по п.1, отличающееся тем, что представляет изотип lgG1.5. Антитело по п.1, отличающееся тем, что включает вариабельную последовательность тяжелой цепи, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 и 42, и вариабельную последовательность легкой цепи, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 и 44.6. Выделенное полностью человеческое моноклональное антитело, включающее вариабельную последовательность тяжелой цепи, содержащую аминокислотную последовательность по SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 и 42, и вариабельную последовательность легкой цепи, содержащую аминокислотную последовательность по SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 и 44, причем указанное антитело связывает IL-17F.7. Антитело по п.6, отличающееся тем, что связывает гомодимер IL-17A.8.
Claims (20)
1. Выделенное полностью человеческое моноклональное анти-IL-17F антитело, или его фрагмент, где указанное антитело включает:
(a) область VH CDR1, содержащую аминокислотную последовательность по SEQ ID NO: 45, 48, 51, 64, 67 или 70;
(b) область VH CDR2, содержащую аминокислотную последовательность по SEQ ID NO: 46, 49, 52, 54, 62, 65, 68, 71 или 73;
(c) область VH CDR3, содержащую аминокислотную последовательность по SEQ ID NO: 47, 50, 53, 55, 63, 66, 69 или 72;
(d) область VL CDR1, содержащую аминокислотную последовательность по SEQ ID NO: 74, 77, 80, 85, 91 или 94;
(e) область VL CDR2, содержащую аминокислотную последовательность по SEQ ID NO: 75, 78, 81, 83, 86, 92 или 96; и
(f) область VL CDR3, содержащую аминокислотную последовательность по SEQ ID NO: 76, 79, 82, 84, 93, 95, 97, 98 и 99, причем указанное антитело связывает IL-17F.
2. Антитело по п.1, отличающееся тем, что не связывает гомодимер IL-17A.
3. Антитело по п.1, отличающееся тем, что представляет изотип IgG.
4. Антитело по п.1, отличающееся тем, что представляет изотип lgG1.
5. Антитело по п.1, отличающееся тем, что включает вариабельную последовательность тяжелой цепи, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 и 42, и вариабельную последовательность легкой цепи, содержащую аминокислотную последовательность, выбранную из SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 и 44.
6. Выделенное полностью человеческое моноклональное антитело, включающее вариабельную последовательность тяжелой цепи, содержащую аминокислотную последовательность по SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 и 42, и вариабельную последовательность легкой цепи, содержащую аминокислотную последовательность по SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 и 44, причем указанное антитело связывает IL-17F.
7. Антитело по п.6, отличающееся тем, что связывает гомодимер IL-17A.
8. Антитело по п.7, отличающееся тем, что представляет изотип IgG.
9. Фармацевтическая композиция, отличающаяся тем, что содержит антитело по п.1 и носитель.
10. Фармацевтическая композиция, отличающаяся тем, что содержит антитело по п.6 и носитель.
11. Способ облегчения симптома клинического показания, ассоциированного с ревматоидным артритом, болезнью Крона, псориазом, рассеянным склерозом, хронической обструктивной болезнью легких или астмой у субъекта, включающий стадию, на которой вводят антагонист IL-17F нуждающемуся в этом субъекту в количестве, достаточном для облегчения симптома клинического показания, ассоциированного с ревматоидным артритом, болезнью Крона, псориазом, рассеянным склерозом, хронической обструктивной болезнью легких или астмой.
12. Способ по п.11, отличающийся тем, что указанный субъект является человеком.
13. Способ по п.11, отличающийся тем, что указанный антагонист является моноклональным антителом или его фрагментом.
14. Способ по п.13, отличающийся тем, что указанное моноклональное антитело представляет собой антитело по п.1 или его фрагмент.
15. Способ облегчения симптома аутоиммунной болезни или воспалительного расстройства, включающий введение антитела по п.1 нуждающемуся в этом субъекту в количестве, достаточном для облегчения симптома аутоиммунной болезни или воспалительного расстройства у субъекта.
16. Способ по п.15, отличающийся тем, что указанный субъект является человеком.
17. Способ облегчения симптома артритного состояния, включающий введение антитела по п.1 нуждающемуся в этом субъекту в количестве, достаточном для облегчения симптома артритного состояния у субъекта.
18. Способ по п.17, отличающийся тем, что указанный субъект является человеком.
19. Способ по п.17, отличающийся тем, что артритное состояние является аутоиммунным артритным состоянием.
20. Способ по п.17, отличающийся тем, что артритное состояние является ревматоидным артритом.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17551209P | 2009-05-05 | 2009-05-05 | |
| US61/175,512 | 2009-05-05 | ||
| PCT/IB2010/001436 WO2010128407A2 (en) | 2009-05-05 | 2010-05-05 | Anti-il-17f antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011149334A true RU2011149334A (ru) | 2013-06-10 |
| RU2605318C2 RU2605318C2 (ru) | 2016-12-20 |
Family
ID=42973557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011149334/10A RU2605318C2 (ru) | 2009-05-05 | 2010-05-05 | Анти-il-17f антитела и способы их применения |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8137671B2 (ru) |
| EP (1) | EP2427203B1 (ru) |
| JP (2) | JP6053517B2 (ru) |
| KR (1) | KR101811886B1 (ru) |
| CN (2) | CN102458437B (ru) |
| AU (1) | AU2010244142B2 (ru) |
| BR (1) | BRPI1014544B8 (ru) |
| CA (1) | CA2759848C (ru) |
| CL (1) | CL2011002744A1 (ru) |
| HK (1) | HK1215038A1 (ru) |
| IL (1) | IL215795A (ru) |
| MX (2) | MX2011011729A (ru) |
| PE (2) | PE20120815A1 (ru) |
| RU (1) | RU2605318C2 (ru) |
| SG (1) | SG175276A1 (ru) |
| WO (1) | WO2010128407A2 (ru) |
| ZA (1) | ZA201107555B (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641822B1 (en) | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| PE20120815A1 (es) * | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CA2841577C (en) | 2011-07-11 | 2018-12-04 | Indi Molecular, Inc. | Akt-specific capture agents, compositions, and methods of using and making |
| US10131709B2 (en) | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| AU2013206788B2 (en) * | 2011-12-28 | 2017-11-30 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| AP2015008584A0 (en) | 2013-02-08 | 2015-07-31 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| TW201628647A (zh) * | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US9913875B2 (en) | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| CN115112898A (zh) * | 2015-07-15 | 2022-09-27 | 加州理工学院 | Il-17f-特异性捕获剂、组合物以及使用和制造的方法 |
| JP6931648B2 (ja) * | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| EP3519425B1 (en) | 2016-09-29 | 2024-02-28 | Indi Molecular, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same |
| US10858427B2 (en) | 2017-03-10 | 2020-12-08 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Monoclonal antibody against both IL-17A and IL-17F and use of the same |
| WO2018232345A1 (en) | 2017-06-15 | 2018-12-20 | Indi Molecular, Inc. | Il-17f and il-17a-specific capture agents, compositions, and methods of using and making |
| US12201679B2 (en) | 2019-04-05 | 2025-01-21 | Institute For Systems Biology | Epitope-targeted peptide immunostimulants |
| US12216122B2 (en) | 2019-05-20 | 2025-02-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) |
| US12209142B2 (en) | 2020-05-29 | 2025-01-28 | Institute For Systems Biology | SARS-CoV-2 epitope-targeted peptide immunostimulants |
| WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
Family Cites Families (202)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4738681A (en) * | 1985-07-10 | 1988-04-19 | Harrington Arthritis Research Center | Femoral-joint prosthetic device |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5370870A (en) * | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| WO1992010210A1 (en) | 1990-12-14 | 1992-06-25 | E.I. Du Pont De Nemours And Company | Inhibition of angiogenesis by il-1 |
| US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JPH07500820A (ja) | 1991-09-05 | 1995-01-26 | ユニバーシティ オブ コネティカット | ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達 |
| US5273033A (en) * | 1991-09-19 | 1993-12-28 | Murray Electronics Associates Limited Partnership | Electrical stimulation for treatment of osteoarthritis |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| EP0592677B1 (en) | 1992-02-18 | 2001-11-07 | Otsuka Kagaku Kabushiki Kaisha | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5536637A (en) * | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69425890D1 (de) | 1993-06-04 | 2000-10-19 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
| WO2000073452A2 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0817847T4 (da) * | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5573762A (en) * | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| EP1591529A3 (en) | 1995-07-19 | 2005-11-09 | Genetics Institute, LLC | Human CLTA-8 and uses of CTLA-8-related proteins |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
| KR19990077146A (ko) | 1996-01-11 | 1999-10-25 | 길리스 스티브 | 유방암의 치료 및 진단용 조성물 및 방법 |
| US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| ATE429241T1 (de) * | 1996-11-27 | 2009-05-15 | Immunex Corp | Verfahren zur regulierung der stickstoffmonoxid- erzeugung |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6054559A (en) * | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| US20020177188A1 (en) * | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| WO2000070050A1 (en) | 1999-05-14 | 2000-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2001046420A2 (en) | 1999-12-23 | 2001-06-28 | Genentech, Inc. | Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
| US6569645B2 (en) * | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6579520B2 (en) * | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| KR20010012111A (ko) | 1997-04-25 | 2001-02-15 | 리스 데브라 케이. | 포유동물의 사이토킨-유사 인자 7 |
| EP1012260A4 (en) | 1997-07-16 | 2001-05-09 | Human Genome Sciences Inc | INTERLEUKINE-20 |
| US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| AU9482498A (en) | 1997-09-17 | 1999-04-05 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| US6562578B1 (en) * | 1999-01-11 | 2003-05-13 | Schering Corporation | IL-17-like cytokine binding compounds and antibodies |
| WO1999032632A1 (en) | 1997-12-19 | 1999-07-01 | Millennium Pharmaceuticals, Inc. | Novel embryo-derived interleukin related factor molecules and uses therefor |
| KR100685105B1 (ko) | 1997-12-19 | 2007-02-22 | 와이어쓰 | 연골의 퇴행성 질환용 트랜스제닉 동물 모델 |
| AU2031399A (en) | 1998-01-09 | 1999-07-26 | Immunex Corporation | Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides |
| DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
| NZ528703A (en) | 1998-03-25 | 2005-05-27 | Genentech Inc | Novel PRO337 polypeptides and nucleic acids encoding a neurotrimin polypeptide |
| ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| NZ508878A (en) * | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| EP1443055A3 (en) | 1998-05-29 | 2005-06-08 | Human Genome Sciences, Inc. | Interleukins-21 and 22 |
| US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
| DE69937570T2 (de) | 1998-09-17 | 2009-04-23 | Zymogenetics, Inc., Seattle | Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren |
| AU6277799A (en) | 1998-10-02 | 2000-04-26 | Eli Lilly And Company | Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| AR022237A1 (es) | 1999-01-11 | 2002-09-04 | Schering Corp | Citoquinas mamiferas purificadas; reactivos y metodos relacionados |
| WO2000042188A2 (en) | 1999-01-11 | 2000-07-20 | Schering Corporation | Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses |
| AU2596700A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| AU3921600A (en) | 1999-03-25 | 2000-10-09 | Abbott Gmbh & Co. Kg | Human antibodies that bind human il-12 and methods for producing |
| US20030082734A1 (en) * | 1999-06-01 | 2003-05-01 | Dowling Lynette M. | Mammalian receptor proteins; related reagents and methods |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US20030199041A1 (en) * | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
| CA2378519C (en) | 1999-07-07 | 2011-01-25 | Zymogenetics, Inc. | Human cytokine receptor |
| WO2001012659A2 (en) | 1999-08-18 | 2001-02-22 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Human dna sequences |
| EP1208202A2 (en) | 1999-09-01 | 2002-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2003508088A (ja) | 1999-09-03 | 2003-03-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５２個のヒト分泌タンパク質 |
| AU7445900A (en) * | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| AU3434601A (en) | 1999-11-30 | 2001-06-12 | Genentech Inc. | Compositions and methods for the treatment of immune related diseases |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| US20040034192A1 (en) | 2000-01-06 | 2004-02-19 | Seishi Kato | Human proteins having hyprophobic domains and dnas encoding these proteins |
| AU2001233041A1 (en) | 2000-01-25 | 2001-08-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CA2395857A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2001236638A1 (en) | 2000-02-04 | 2001-08-14 | The Board Of Trustees Of The University Of Arkansas | Evi27 gene sequences and protein encoded thereby |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AR030554A1 (es) | 2000-03-16 | 2003-08-27 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
| US7094566B2 (en) * | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
| WO2001068859A2 (en) | 2000-03-16 | 2001-09-20 | Amgen Inc. | Il-17 receptor like molecules and uses thereof |
| DE60120372T2 (de) * | 2000-03-24 | 2007-07-05 | Genentech Inc., San Francisco | Verwendung von insulin zur behandlung von knorpelkrankheiten |
| DE60136921D1 (de) | 2000-04-18 | 2009-01-22 | Schering Corp | Medizinische Verwendung von IL-174 Agonisten und Antagonisten |
| EP1287130B2 (en) * | 2000-05-10 | 2017-07-26 | Merck Sharp & Dohme Corp. | Mammalian cytokine receptor subunit proteins, related reagents and methods |
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| MXPA02011617A (es) | 2000-05-24 | 2003-03-10 | Schering Corp | Proteinas de mamiferos receptoras, reactivosy metodos relacionados. |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030096969A1 (en) * | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| ES2444710T3 (es) | 2000-06-22 | 2014-02-26 | Amgen, Inc. | Uso de un anticuerpo específico para un polipéptido similar a IL-17 |
| CA2416456A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2427824A1 (en) | 2000-07-26 | 2002-01-31 | Zymogenetics, Inc. | Human cytokine receptor |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| JP2002139499A (ja) * | 2000-08-23 | 2002-05-17 | Sanyo Electric Co Ltd | 化学物質センサおよび化学物質の検出方法 |
| JP2002076897A (ja) * | 2000-08-29 | 2002-03-15 | Toshiba Corp | Ｄａコンバータ |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| AU2002324625B2 (en) * | 2001-08-07 | 2008-05-08 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| CA2421692A1 (en) * | 2002-03-12 | 2003-09-12 | David J. Pisani | Disposable bedding with absorbent region |
| DK1576011T3 (da) | 2002-10-30 | 2009-11-30 | Genentech Inc | Inhibering af IL-17 produktion |
| SI1601694T1 (sl) * | 2003-03-10 | 2010-01-29 | Schering Corp | Uporabe IL-23 antagonistov; sorodni reagenti |
| EP1644415B1 (en) | 2003-06-23 | 2010-12-01 | Genetics Institute, LLC | Antibodies against interleukin-22 and uses therefor |
| EP1641822B1 (en) * | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| WO2005046603A2 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
| AU2004289303A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| DK1983000T3 (en) | 2003-11-21 | 2015-12-07 | Ucb Biopharma Sprl | A method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| JP4903061B2 (ja) * | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Ｉｌ−２３活性を調節する方法；関連する試薬 |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| TW200641353A (en) * | 2005-02-14 | 2006-12-01 | Wyeth Corp | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| CA2610709A1 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
| CN101296706B (zh) | 2005-09-01 | 2011-11-30 | 先灵公司 | Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途 |
| UA96139C2 (ru) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитело к нейропилину-1 (nrp1) |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| EP2377887A1 (en) * | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| WO2008134659A2 (en) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| AU2007352412B2 (en) * | 2007-04-27 | 2013-05-16 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| WO2009015063A2 (en) | 2007-07-23 | 2009-01-29 | Centocor | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
| WO2009026412A1 (en) | 2007-08-21 | 2009-02-26 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| PE20120815A1 (es) * | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| AU2010313304B2 (en) | 2009-10-30 | 2015-08-20 | Janssen Biotech, Inc. | IL-17A antagonists |
-
2010
- 2010-05-05 PE PE2011001898A patent/PE20120815A1/es active IP Right Grant
- 2010-05-05 SG SG2011076544A patent/SG175276A1/en unknown
- 2010-05-05 US US12/774,188 patent/US8137671B2/en not_active Expired - Fee Related
- 2010-05-05 CN CN201080029508.4A patent/CN102458437B/zh not_active Expired - Fee Related
- 2010-05-05 WO PCT/IB2010/001436 patent/WO2010128407A2/en not_active Ceased
- 2010-05-05 PE PE2016000640A patent/PE20160652A1/es unknown
- 2010-05-05 RU RU2011149334/10A patent/RU2605318C2/ru not_active Application Discontinuation
- 2010-05-05 BR BRPI1014544A patent/BRPI1014544B8/pt not_active IP Right Cessation
- 2010-05-05 MX MX2011011729A patent/MX2011011729A/es active IP Right Grant
- 2010-05-05 JP JP2012509113A patent/JP6053517B2/ja not_active Expired - Fee Related
- 2010-05-05 EP EP10739395.1A patent/EP2427203B1/en active Active
- 2010-05-05 KR KR1020117028978A patent/KR101811886B1/ko not_active Expired - Fee Related
- 2010-05-05 MX MX2014012530A patent/MX348013B/es unknown
- 2010-05-05 AU AU2010244142A patent/AU2010244142B2/en not_active Ceased
- 2010-05-05 CA CA2759848A patent/CA2759848C/en not_active Expired - Fee Related
- 2010-05-05 CN CN201510244501.9A patent/CN104974250A/zh active Pending
-
2011
- 2011-10-14 ZA ZA2011/07555A patent/ZA201107555B/en unknown
- 2011-10-23 IL IL215795A patent/IL215795A/en active IP Right Grant
- 2011-11-04 CL CL2011002744A patent/CL2011002744A1/es unknown
-
2012
- 2012-03-01 US US13/409,585 patent/US8609093B2/en not_active Expired - Fee Related
-
2013
- 2013-11-12 US US14/078,062 patent/US20140099322A1/en not_active Abandoned
-
2014
- 2014-10-06 US US14/507,108 patent/US9475873B2/en not_active Expired - Fee Related
-
2015
- 2015-07-03 JP JP2015134163A patent/JP2016006051A/ja not_active Withdrawn
-
2016
- 2016-03-16 HK HK16103049.7A patent/HK1215038A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| CN109071654B (zh) | 靶向Fc受体样5的抗体及使用方法 | |
| JP2010526028A5 (ru) | ||
| JP2007527406A5 (ru) | ||
| JP2014526898A5 (ru) | ||
| JP2012501669A5 (ru) | ||
| JP2011520898A5 (ru) | ||
| JP2020508655A5 (ru) | ||
| RU2011101589A (ru) | Антитела против il-6 и их применение | |
| JP2007530068A5 (ru) | ||
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| JP2012532851A5 (ru) | ||
| JP2020534830A5 (ru) | ||
| JP2014500009A5 (ru) | ||
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2012501670A5 (ru) | ||
| JP2010502183A5 (ru) | ||
| JP2015535820A5 (ru) | ||
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| RU2017128882A (ru) | Антитела к биотину и способы их применения | |
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| WO2022105914A1 (zh) | Cd70抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140908 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20141001 |